New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07195617
Summary
This early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy for people with relapsed or refractory multiple myeloma who have already tried at least three other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target two proteins on the cancer cells, and then infuse them back into the patient. The study will closely monitor patients for side effects and how well the cancer responds for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.